Digital Rectal Exam (DRE) Articles

Articles

Beyond the Abstract - Could prostate biopsies be avoided in men older than 75 years with raised PSA? by Michael Nomikos, MD, FEBU

BERKELEY, CA (UroToday.com) - The 10-year rule is the most frequently cited life expectancy benchmark for delivery of definitive therapy to patients with clinically localized prostate cancer.

Published April 18, 2011
Prostate Health Index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml, "Beyond the Abstract," by Daniela Terracciano, et al.

BERKELEY, CA (UroToday.com) - Despite the overall success of PSA, its use as a serum marker for prostate cancer leaves much to be desired. The primary limitation of PSA has been its inability to accurately distinguish between a benign and malignant pathology.
Published November 12, 2013